Core Viewpoint - The article highlights the journey of Zhenmai Biotechnology in developing a domestically produced gene sequencer, overcoming significant challenges in a field dominated by foreign companies, and achieving substantial growth and innovation in the industry [1][2]. Company Overview - Zhenmai Biotechnology, founded in 2012, has become one of only three companies globally capable of providing full-flow sequencing instruments, achieving 100% self-research and production of core materials [1][3]. - The company has developed the world's fastest second-generation sequencer, FASTASeq S, which significantly reduces detection times for infections and tumors [6]. Financial Performance - The company reports an average annual revenue growth of 80% to 90%, with projected revenue nearing 400 million yuan this year, reaching a break-even point [1][6]. - Future annual performance growth is expected to maintain between 60% and 80% [1][6]. Technological Challenges - The development of gene sequencers involves complex innovations across over 20 disciplines, including optics, fluid mechanics, and biochemistry, with any shortcomings potentially impacting sequencing accuracy and costs [2][4]. - The industry faces a challenge in defining standards, as the current benchmarks have been set by dominant players like Illumina, which Zhenmai aims to surpass [7]. Market Strategy - Zhenmai's strategy includes a focus on building a closed-loop system that integrates devices, reagents, and ecological systems, which is crucial for gaining market acceptance and establishing a competitive edge [8]. - The company has expanded its international presence, with overseas revenue accounting for 50% and partnerships in over 60 countries [8]. Vision for the Future - The company's vision is to transition from "Made in China" to an internationally recognized brand, aiming to influence global standards and quality in the biotechnology sector [9].

文 ｜ 陈竹 宋硕 曾令鹏 张斌斌 李文涛 顾资然 根据2 0 2 5年3月4日商务部官网，依据不可靠实体清单工作机制，禁止因美纳公司（Ill umi n a , I n c .）向中国出口基因测序仪，基因测序仪类比生命科学上游的"光刻机"，我国生命科学产业发展 迎来了重大转折时刻，开启全面自主可控，加速国产替代新阶段。 ▍ 中国生命科学产业发展迎来了重大转折时刻。 根据商务部官网，依据《不可靠实体清单规定》有关规定，不可靠实体清单工作机制决定于2 0 2 5 年2月4日将美国因美纳公司（Ill umi n a , I n c .）列入不可靠实体清单。2 0 2 5年3月4日，明确决定 对因美纳公司（Ill umi n a , I n c .）采取"禁止其向中国出口基因测序仪"措施。我们认为中国生命科 学产业发展迎来了重大转折时刻，国产公司全力对于已经和Ill umi n a建立长期合作关系的终端而 言，可能潜在面临试剂短缺、设备维修保养困难等问题，在转向新的检测平台之前，原有的检测 业务可能直接面临停摆风险。 ▍ 基因测序仪行业增速快、壁垒高、前景好，国产替代加速。 根据JPM c o n f e r e ...